Epigenetic Reader Domain
Epigenetic regulators play a crucial role in controlling gene expression and modifying the chromatin state. These regulators can be categorized as "writers", "erasers", and "readers" of chromatin modifications. Readers are known for their specific domain interactions with modified chromatin. For instance, bromodomains are commonly associated with acetyllysine binding, while chromo, malignant brain tumor (MBT), plant homeodomain (PHD), and Tudor domains are often associated with methyllysine recognition.
The identification of selective inhibitors targeting bromodomains, such as the bromodomain and extra terminal motif (BET) family, has greatly advanced the field of epigenetic reader research. Notably, the human genome contains 46 proteins with a total of 61 bromodomains grouped into eight families.
For more details about our epigenetic reader domain products, please click the links listed below.
- (-)-Epigallocatechin Gallate
-
CAT#:
DEERD-2312-LGZ-1
-
CAS Number:
989-51-5
-
Application:
Antioxidant, Antiangiogenic, Antitumor agent
- PF-03814735
-
CAT#:
DEERD-2312-LGZ-4
-
CAS Number:
942487-16-3
-
Application:
Aurora A/B Kinase Inhibitor
- GSK 525762A (I-BET-762)
-
CAT#:
DEERD-2312-LGZ-5
-
CAS Number:
1260907-17-2
-
Application:
BET Inhibitor
- GSK 1210151A (I-BET151)
-
CAT#:
DEERD-2312-LGZ-6
-
CAS Number:
1300031-49-5
-
Application:
BET Bromodomain Inhibitor
- GSK9311
-
CAT#:
DEERD-2312-LGZ-9
-
CAS Number:
1923851-49-3
-
Application:
Inhibitor of the BRPF Bromodomain